Kazia Therapeutics Current ratio
Cos'è Current ratio di Kazia Therapeutics?
Current ratio di Kazia Therapeutics Limited è 0.71
Qual è la definizione di Current ratio?
Il rapporto corrente è un rapporto di liquidità che misura se una società dispone o meno di risorse sufficienti per soddisfare i suoi obblighi a breve termine.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio di aziende nel Health Care settore su ASX rispetto a Kazia Therapeutics
Cosa fa Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Aziende con current ratio simili a Kazia Therapeutics
- Mei Ah Entertainment ha Current ratio di 0.71
- NuZee ha Current ratio di 0.71
- Gran Tierra ha Current ratio di 0.71
- Cousins Properties ha Current ratio di 0.71
- Adani Enterprises ha Current ratio di 0.71
- Digital Realty Trust Inc ha Current ratio di 0.71
- Kazia Therapeutics ha Current ratio di 0.71
- Digital Realty Trust ha Current ratio di 0.71
- Digital Realty Trust ha Current ratio di 0.71
- Cassiar Gold Corp ha Current ratio di 0.71
- Ackermans & van Haaren NV ha Current ratio di 0.71
- U.S. Xpress Enterprises Inc ha Current ratio di 0.71
- On Real International ha Current ratio di 0.71